AI-enabled pharmaceutical R&D market growing quickly

Chinese players making waves on global stage in promising sector

Artificial intelligence has drawn billions of dollars in global investment as pharmaceutical giants race to accelerate new drug development, yet the AI drug discovery sector is still defining its viable commercial models. In China's vibrant biotech ecosystem, two industry heavyweights with deep roots in the country are now offering different answers.

Recent financial results from XtalPi Holdings Ltd and InSilico Medicine Cayman TopCo show the sector diverging into two distinct business models — one built on selling AI-powered research services, the other on using algorithms to create entirely new biotech pipelines.